Annexon, Inc. (ANNX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to the ANNX on business update call. At this time, all attendees are in a listen only mode, and a question and answer session will follow the formal remarks. As a reminder, this call is being recorded, and a replay will be made available on the ANNX on website following the conclusion of the event. I'd now like to turn the call over to Doug Love, president and chief executive officer of ANNXON. Please go ahead, Doug. Thank you, operator. Good morning, and welcome, everyone. Earlier this morning, ANNXON issued a press release announcing that we have expanded our ARCHER II Phase III trial for vodipruma in geographic atrophy and a press release announcing key business updates and second quarter financial results. Copies of these press releases are available on the company's website and through our SEC filings. On today's call, we will be making forward looking statements, including statements relating to the existing clinical data and the therapeutic and commercial potential of our investigational drug candidates. Joining me today are Doctor. Jamie Dannenberg, our EVP and chief medical officer, and doctor Lloyd Clark, SVP of ophthalmology strategy and innovation, who will discuss our GBS and GA programs, respectively. I will then close before we open the call for questions. We will be joined by doctor Chad Yednok, EVP and chief innovation officer, and Jin Liu, our chief financial officer. Before we turn to the updates, I'd like to briefly frame ANNXON's broader opportunity and our excitement about building a leading fully integrated biotech company driven by our mission to help millions of people live their best lives. Annexon was founded on discoveries from Stanford University to create a new class of targeted immunotherapies that st...